Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Adenosine as a potential analgesic target in inflammatory and neuropathic pains
Autore:
Dickenson, AH; Suzuki, R; Reeve, AJ;
Indirizzi:
Univ London Univ Coll, Dept Pharmacol, London WC1E 6BT, England Univ London Univ Coll London England WC1E 6BT , London WC1E 6BT, England
Titolo Testata:
CNS DRUGS
fascicolo: 2, volume: 13, anno: 2000,
pagine: 77 - 85
SICI:
1172-7047(200002)13:2<77:AAAPAT>2.0.ZU;2-Q
Fonte:
ISI
Lingua:
ENG
Soggetto:
RAT SPINAL-CORD; PRIMARY AFFERENT NEURONS; DORSAL HORN NEURONS; R-PHENYLISOPROPYL-ADENOSINE; RECEPTOR ACTIVATION; NMDA-RECEPTOR; FORMALIN TEST; INTRATHECAL INJECTION; HEALTHY-VOLUNTEERS; PERIPHERAL NEUROPATHY;
Tipo documento:
Review
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Life Sciences
Citazioni:
107
Recensione:
Indirizzi per estratti:
Indirizzo: Dickenson, AH Univ London Univ Coll, Dept Pharmacol, Gower St, London WC1E6BT, England Univ London Univ Coll Gower St London England WC1E 6BT land
Citazione:
A.H. Dickenson et al., "Adenosine as a potential analgesic target in inflammatory and neuropathic pains", CNS DRUGS, 13(2), 2000, pp. 77-85

Abstract

Substantial evidence exists for the physiological role of adenosine in themodulation of primary afferent transmission. Since the first description of the antinociceptive effects of adenosine, there has been considerable interest in the development of adenosine analogues as potential analgesics forthe treatment of various pain states. The direction of effect of adenosinein the periphery is complicated by the existence of multiple receptors andspecies differences. The analgesic actions of agents acting on adenosine receptor systems are largely attributed to actions at the spinal cord. Two subtypes of adenosine receptors (A(1) and A(2)) have been identified in the substantia gelatinosa of the spinal cord where they were shown to be localised primarily on intrinsic neurons. Although evidence exists for the involvement of A(2) receptors in spinally mediated antinociception, it appears tobe predominantly the A(1) receptor subtype which plays a major role in inhibiting the nociceptive input in the dorsal spinal cord. The antinociceptive properties of adenosine and receptor-selective analogues have been demonstrated across a wide range of animal models, including acute nociceptive tests and in models of inflammation and neuropathy. These results, observed across several models of pain, strongly support the potential clinical use of these agents in various pain states. In humans, systemic or intrathecal administration of adenosine was shown to be effective against experimentally induced pain in healthy volunteers. Subsequently, thereis evidence for the effectiveness of systemic and spinally administered adenosine in patients with neuropathic pain. A number of studies have demonstrated possible interactions between adenosine and glutamate in the spinal cord, and between N-methyl-D-aspartate receptor activation and adenosine release elsewhere in the brain. There is alsosome evidence that drugs acting to inhibit the metabolism of adenosine mayhave therapeutic potential in pain states. In this context, the release ofadenosine appears to be elevated in hyperexcitable neuronal systems. This would allow therapies to selectively target active neurons in pain systems and therefore would be expected to have low adverse effect liability.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 07/07/20 alle ore 15:27:01